Special Issue

Lentiviral Vectors

Message from the Guest Editor

Research on lentiviruses has been intensive and provided the basis for the development of lentiviral vector (LV) systems. While HIV-1-derived LV are routinely used in a wide range of basic biology research, recent advances leading to their clinical use. Research and development of LVs based on non-human lentivirus species, such as SIV and FIV, has also been substantial and the use of heterologous, non-lentiviral envelopes in LV systems relies on wider virology research. Additionally, clinical translation and development of LV systems to realize improved efficacy and safety requires multi-disciplinary efforts beyond virology to address key issues, such as biologics manufacturing, anti-LV host immune responses and LV-mediated genotoxicity. While LV development benefits from virologic and other research areas, it is noted that LV research can, in turn, provide valuable advanced research tools and insights as well as novel research ideas and questions. This special issue is calling for reviews and original papers in this wide area of research related to lentiviral vectors.

Guest Editor

Dr. Yasuhiro Takeuchi

Infection and Immunity, University College London (UCL): Advanced Therapies, National Institute for Biological Standards and Control (NIBSC), Hertfordshire, UK

Deadline for manuscript submissions

closed (31 March 2022)

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/39904

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/viruses

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/viruses

About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed
HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).